UMIN-CTR Clinical Trial

Recruitment status Terminated
Unique ID issued by UMIN UMIN000041453
Receipt No. R000047322
Scientific Title Adverse events of combined Dabrafenib Plus Trametinib in the treatment of tumors: a systematic review and meta-analysis.
Date of disclosure of the study information 2020/08/18
Last modified on 2021/02/17 (Ver. 2)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Adverse events of combined Dabrafenib Plus Trametinib in the treatment of tumors: a systematic review and meta-analysis.
Acronym Adverse events of combined Dabrafenib Plus Trametinib in the treatment of tumors: a systematic review and meta-analysis.
Scientific Title Adverse events of combined Dabrafenib Plus Trametinib in the treatment of tumors: a systematic review and meta-analysis.
Scientific Title:Acronym Adverse events of combined Dabrafenib Plus Trametinib in the treatment of tumors: a systematic review and meta-analysis.
Region
Japan Asia(except Japan) North America
South America Australia Europe
Africa

Condition
Condition tumors
Classification by specialty
Pneumology Adult
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Adverse events of combined Dabrafenib Plus Trametinib in the treatment of tumors
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Not applicable

Assessment
Primary outcomes category fo adverse event
Key secondary outcomes frequency of adverse event

Base
Study type Others,meta-analysis etc

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
12 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria treated with dabrafenib and trametinib
Key exclusion criteria Without frequency or category of adverse event
Target sample size

Research contact person
Name of lead principal investigator
1st name Kou
Middle name
Last name Chin
Organization Yokohama city university
Division name pulmonology
Zip code 2360004
Address 3-9 Fukuura, Kanazawa, Yokohama 236-0004, Japan
TEL 045-352-7962
Email chinksmd@yahoo.co.jp

Public contact
Name of contact person
1st name Kou
Middle name
Last name Chin
Organization Yokohama city university
Division name Pulomonology
Zip code 2360004
Address 3-9 Fukuura, Kanazawa, Yokohama 236-0004, Japan
TEL 045-352-7962
Homepage URL
Email chinksmd@yahoo.co.jp

Sponsor
Institute 3-9 Fukuura, Kanazawa, Yokohama 236-0004, Japan
Institute
Department

Funding Source
Organization 3-9 Fukuura, Kanazawa, Yokohama 236-0004, Japan
Organization
Division
Category of Funding Organization Government offices of other countries
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Yokohama city university
Address 3-9 Fukuura, Kanazawa, Yokohama 236-0004, Japan
Tel 045-352-7962
Email chinksmd@yahoo.co.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 08 Month 18 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2020 Year 08 Month 18 Day
Date of IRB
2020 Year 08 Month 18 Day
Anticipated trial start date
2020 Year 08 Month 18 Day
Last follow-up date
2020 Year 08 Month 18 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information none

Management information
Registered date
2020 Year 08 Month 18 Day
Last modified on
2021 Year 02 Month 17 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000047322